Pasithea Therapeutics Corp. KTTA
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Pasithea Therapeutics Corp. (KTTA) is a healthcare company listed in the US with a market value of about $17M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -38%.
About Pasithea Therapeutics
Pasithea Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 5 years in our data. Its share count rose by 457% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $486559 | $15062 |
| Net income | -$20M | -$14M | -$16M | -$14M | -$2M |
| Free cash flow | — | — | -$13M | -$15M | -$3M |
| EPS (diluted) | $-0.58 | $-2.54 | $-0.08 | $-0.35 | $-0.84 |
| Net margin | — | — | — | -2864.3% | -14430.5% |
| ROIC | -29.8% | -76.1% | -53.8% | -23.1% | -6.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $4.00, 666% above the current price; targets range from $4.00 to $4.00; the consensus rating is “Strong buy”; expected EPS is $-0.76 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Pasithea Therapeutics pay a dividend?
Not currently.
Is Pasithea Therapeutics a good stock to buy?
We do not give buy or sell advice. Pasithea Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.